Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.

Autor: Barsheshet Y; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Voloshin T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Brant B; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Cohen G; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Koren L; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Blatt R; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Cahal S; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Haj Khalil T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Zemer Tov E; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Paz R; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Klein-Goldberg A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Tempel-Brami C; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Jacobovitch S; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Volodin A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Kan T; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Koltun B; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., David C; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Haber A; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Giladi M; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Weinberg U; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel., Palti Y; Novocure Ltd., Topaz Building, MATAM Center, Haifa 31905, Israel.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 15; Vol. 23 (22). Date of Electronic Publication: 2022 Nov 15.
DOI: 10.3390/ijms232214073
Abstrakt: Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields induce anti-mitotic effects through the disruption of the mitotic spindle and abnormal chromosome segregation, which trigger several forms of cell death, including immunogenic cell death (ICD). The efficacy of TTFields concomitant with anti-programmed death-1 (anti-PD-1) treatment was previously shown in vivo and is currently under clinical investigation. Here, the potential of TTFields concomitant with anti- PD-1/anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed death-ligand 1 (anti-PD-L1) immune checkpoint inhibitors (ICI) to improve therapeutic efficacy was examined in lung tumor-bearing mice. Increased circulating levels of high mobility group box 1 protein (HMGB1) and elevated intratumoral levels of phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α) were found in the TTFields-treated mice, indicative of ICD induction. The concomitant application of TTFields and ICI led to a significant decrease in tumor volume as compared to all other groups. In addition, significant increases in the number of tumor-infiltrating immune cells, specifically cytotoxic T-cells, were observed in the TTFields plus anti-PD-1/anti-CTLA-4 or anti-PD-L1 groups. Correspondingly, cytotoxic T-cells isolated from these tumors showed higher levels of IFN-γ production. Collectively, these results suggest that TTFields have an immunoactivating role that may be leveraged for concomitant treatment with ICI to achieve better tumor control by enhancing antitumor immunity.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje